179 related articles for article (PubMed ID: 19277878)
1. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model.
JuanYin J; Tracy K; Zhang L; Munasinghe J; Shapiro E; Koretsky A; Kelly K
Clin Exp Metastasis; 2009; 26(5):403-14. PubMed ID: 19277878
[TBL] [Abstract][Full Text] [Related]
2. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer.
Yin JJ; Zhang L; Munasinghe J; Linnoila RI; Kelly K
Cancer Res; 2010 Nov; 70(21):8662-73. PubMed ID: 20959486
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI.
Boult JKR; Box G; Vinci M; Perryman L; Eccles SA; Jones C; Robinson SP
Neoplasia; 2017 Sep; 19(9):684-694. PubMed ID: 28780387
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.
Leenders WP; Küsters B; Verrijp K; Maass C; Wesseling P; Heerschap A; Ruiter D; Ryan A; de Waal R
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6222-30. PubMed ID: 15448011
[TBL] [Abstract][Full Text] [Related]
6. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
Kamoun WS; Ley CD; Farrar CT; Duyverman AM; Lahdenranta J; Lacorre DA; Batchelor TT; di Tomaso E; Duda DG; Munn LL; Fukumura D; Sorensen AG; Jain RK
J Clin Oncol; 2009 May; 27(15):2542-52. PubMed ID: 19332720
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy.
Curwen JO; Musgrove HL; Kendrew J; Richmond GH; Ogilvie DJ; Wedge SR
Clin Cancer Res; 2008 May; 14(10):3124-31. PubMed ID: 18483380
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.
Pishko GL; Muldoon LL; Pagel MA; Schwartz DL; Neuwelt EA
Fluids Barriers CNS; 2015 Feb; 12():5. PubMed ID: 25879723
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.
Kim LS; Huang S; Lu W; Lev DC; Price JE
Clin Exp Metastasis; 2004; 21(2):107-18. PubMed ID: 15168728
[TBL] [Abstract][Full Text] [Related]
10. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
[TBL] [Abstract][Full Text] [Related]
11. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
12. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts.
Bhujwalla ZM; Artemov D; Natarajan K; Ackerstaff E; Solaiyappan M
Neoplasia; 2001; 3(2):143-53. PubMed ID: 11420750
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.
Baker GJ; Yadav VN; Motsch S; Koschmann C; Calinescu AA; Mineharu Y; Camelo-Piragua SI; Orringer D; Bannykh S; Nichols WS; deCarvalho AC; Mikkelsen T; Castro MG; Lowenstein PR
Neoplasia; 2014 Jul; 16(7):543-61. PubMed ID: 25117977
[TBL] [Abstract][Full Text] [Related]
14. Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.
Bradley DP; Tessier JJ; Lacey T; Scott M; Jürgensmeier JM; Odedra R; Mills J; Kilburn L; Wedge SR
Magn Reson Imaging; 2009 Apr; 27(3):377-84. PubMed ID: 18814988
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma.
Küsters B; de Waal RM; Wesseling P; Verrijp K; Maass C; Heerschap A; Barentsz JO; Sweep F; Ruiter DJ; Leenders WP
Cancer Res; 2003 Sep; 63(17):5408-13. PubMed ID: 14500375
[TBL] [Abstract][Full Text] [Related]
16. Real-time imaging reveals the single steps of brain metastasis formation.
Kienast Y; von Baumgarten L; Fuhrmann M; Klinkert WE; Goldbrunner R; Herms J; Winkler F
Nat Med; 2010 Jan; 16(1):116-22. PubMed ID: 20023634
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model.
Masuda C; Sugimoto M; Wakita D; Monnai M; Ishimaru C; Nakamura R; Kinoshita M; Yorozu K; Kurasawa M; Kondoh O; Yamamoto K
Clin Exp Metastasis; 2020 Feb; 37(1):199-207. PubMed ID: 31768815
[TBL] [Abstract][Full Text] [Related]
18. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Sorensen AG; Batchelor TT; Zhang WT; Chen PJ; Yeo P; Wang M; Jennings D; Wen PY; Lahdenranta J; Ancukiewicz M; di Tomaso E; Duda DG; Jain RK
Cancer Res; 2009 Jul; 69(13):5296-300. PubMed ID: 19549889
[TBL] [Abstract][Full Text] [Related]
19. A physiologic imaging pilot study of breast cancer treated with AZD2171.
Miller KD; Miller M; Mehrotra S; Agarwal B; Mock BH; Zheng QH; Badve S; Hutchins GD; Sledge GW
Clin Cancer Res; 2006 Jan; 12(1):281-8. PubMed ID: 16397053
[TBL] [Abstract][Full Text] [Related]
20. The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
Siemann DW; Brazelle WD; Jürgensmeier JM
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):897-903. PubMed ID: 19215823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
